Immunovant (IMVT) Operating Expenses (2018 - 2026)

Immunovant's Operating Expenses history runs 9 years deep, the most recent figure standing at $159.6 million for Q1 2026.

• Quarterly Operating Expenses rose 40.17% year-over-year to $159.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $532.9 million (up 21.63% YoY) and the FY2026 annual result came in at $532.9 million, up 21.62% from the prior year.
• Operating Expenses was $159.6 million for Q1 2026 at Immunovant, up from $114.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $159.6 million in Q1 2026 and bottomed at $40.4 million in Q2 2022.
• A 5-year average of $89.4 million and a median of $80.9 million in 2024 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 94.37% in 2023, while the deepest fall reached 3.86% in 2023.
• Immunovant's Operating Expenses stood at $64.0 million in 2022, then declined by 3.86% to $61.6 million in 2023, then soared by 85.7% to $114.3 million in 2024, then gained by 0.05% to $114.4 million in 2025, then soared by 39.52% to $159.6 million in 2026.
• Business Quant data shows IMVT's Operating Expenses at $159.6 million in Q1 2026, $114.4 million in Q4 2025, and $131.8 million in Q3 2025.